ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Summary
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
Timeline
- Start
- 2018-03-30
- Primary completion
- 2018-11-05
- Completion
- 2018-11-05
Outcome
Met primary endpoint
release “The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of reproxalap.” aldeyra.com ↗
release “In 2019, Aldeyra announced achievement of the primary endpoint of the Phase 3 ALLEVIATE Trial in allergic conjunctivitis” aldeyra.com ↗
release “Primary and key secondary endpoints in allergic conjunctivitis were previously achieved in the Phase 3 ALLEVIATE conjunctival allergen challenge trial” aldeyra.com ↗
release “In the Phase 3 ALLEVIATE Trial, 0.25% reproxalap demonstrated statistically significant reductions from vehicle” aldeyra.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reproxalap | Other / unclassified | 0.25 % | — |
| Subject | Reproxalap | Other / unclassified | 0.5 % | — |